Copyright Reports & Markets. All rights reserved.

Global Blood Cancer Molecular Diagnostics Market Growth (Status and Outlook) 2023-2029

Request for Sample of this report
Buy now

1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered
  • 1.8 Market Estimation Caveats

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Blood Cancer Molecular Diagnostics Market Size 2018-2029
    • 2.1.2 Blood Cancer Molecular Diagnostics Market Size CAGR by Region 2018 VS 2022 VS 2029
  • 2.2 Blood Cancer Molecular Diagnostics Segment by Type
    • 2.2.1 Polymerase Chain Reaction
    • 2.2.2 Molecular Hybridization
    • 2.2.3 Biochip
    • 2.2.4 Others
  • 2.3 Blood Cancer Molecular Diagnostics Market Size by Type
    • 2.3.1 Blood Cancer Molecular Diagnostics Market Size CAGR by Type (2018 VS 2022 VS 2029)
    • 2.3.2 Global Blood Cancer Molecular Diagnostics Market Size Market Share by Type (2018-2023)
  • 2.4 Blood Cancer Molecular Diagnostics Segment by Application
    • 2.4.1 Hospital
    • 2.4.2 Third-Party Testing Agency
    • 2.4.3 Others
  • 2.5 Blood Cancer Molecular Diagnostics Market Size by Application
    • 2.5.1 Blood Cancer Molecular Diagnostics Market Size CAGR by Application (2018 VS 2022 VS 2029)
    • 2.5.2 Global Blood Cancer Molecular Diagnostics Market Size Market Share by Application (2018-2023)

3 Blood Cancer Molecular Diagnostics Market Size by Player

  • 3.1 Blood Cancer Molecular Diagnostics Market Size Market Share by Players
    • 3.1.1 Global Blood Cancer Molecular Diagnostics Revenue by Players (2018-2023)
    • 3.1.2 Global Blood Cancer Molecular Diagnostics Revenue Market Share by Players (2018-2023)
  • 3.2 Global Blood Cancer Molecular Diagnostics Key Players Head office and Products Offered
  • 3.3 Market Concentration Rate Analysis
    • 3.3.1 Competition Landscape Analysis
    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
  • 3.4 New Products and Potential Entrants
  • 3.5 Mergers & Acquisitions, Expansion

4 Blood Cancer Molecular Diagnostics by Regions

  • 4.1 Blood Cancer Molecular Diagnostics Market Size by Regions (2018-2023)
  • 4.2 Americas Blood Cancer Molecular Diagnostics Market Size Growth (2018-2023)
  • 4.3 APAC Blood Cancer Molecular Diagnostics Market Size Growth (2018-2023)
  • 4.4 Europe Blood Cancer Molecular Diagnostics Market Size Growth (2018-2023)
  • 4.5 Middle East & Africa Blood Cancer Molecular Diagnostics Market Size Growth (2018-2023)

5 Americas

  • 5.1 Americas Blood Cancer Molecular Diagnostics Market Size by Country (2018-2023)
  • 5.2 Americas Blood Cancer Molecular Diagnostics Market Size by Type (2018-2023)
  • 5.3 Americas Blood Cancer Molecular Diagnostics Market Size by Application (2018-2023)
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Blood Cancer Molecular Diagnostics Market Size by Region (2018-2023)
  • 6.2 APAC Blood Cancer Molecular Diagnostics Market Size by Type (2018-2023)
  • 6.3 APAC Blood Cancer Molecular Diagnostics Market Size by Application (2018-2023)
  • 6.4 China
  • 6.5 Japan
  • 6.6 Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia

7 Europe

  • 7.1 Europe Blood Cancer Molecular Diagnostics by Country (2018-2023)
  • 7.2 Europe Blood Cancer Molecular Diagnostics Market Size by Type (2018-2023)
  • 7.3 Europe Blood Cancer Molecular Diagnostics Market Size by Application (2018-2023)
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Blood Cancer Molecular Diagnostics by Region (2018-2023)
  • 8.2 Middle East & Africa Blood Cancer Molecular Diagnostics Market Size by Type (2018-2023)
  • 8.3 Middle East & Africa Blood Cancer Molecular Diagnostics Market Size by Application (2018-2023)
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Global Blood Cancer Molecular Diagnostics Market Forecast

  • 10.1 Global Blood Cancer Molecular Diagnostics Forecast by Regions (2024-2029)
    • 10.1.1 Global Blood Cancer Molecular Diagnostics Forecast by Regions (2024-2029)
    • 10.1.2 Americas Blood Cancer Molecular Diagnostics Forecast
    • 10.1.3 APAC Blood Cancer Molecular Diagnostics Forecast
    • 10.1.4 Europe Blood Cancer Molecular Diagnostics Forecast
    • 10.1.5 Middle East & Africa Blood Cancer Molecular Diagnostics Forecast
  • 10.2 Americas Blood Cancer Molecular Diagnostics Forecast by Country (2024-2029)
    • 10.2.1 United States Blood Cancer Molecular Diagnostics Market Forecast
    • 10.2.2 Canada Blood Cancer Molecular Diagnostics Market Forecast
    • 10.2.3 Mexico Blood Cancer Molecular Diagnostics Market Forecast
    • 10.2.4 Brazil Blood Cancer Molecular Diagnostics Market Forecast
  • 10.3 APAC Blood Cancer Molecular Diagnostics Forecast by Region (2024-2029)
    • 10.3.1 China Blood Cancer Molecular Diagnostics Market Forecast
    • 10.3.2 Japan Blood Cancer Molecular Diagnostics Market Forecast
    • 10.3.3 Korea Blood Cancer Molecular Diagnostics Market Forecast
    • 10.3.4 Southeast Asia Blood Cancer Molecular Diagnostics Market Forecast
    • 10.3.5 India Blood Cancer Molecular Diagnostics Market Forecast
    • 10.3.6 Australia Blood Cancer Molecular Diagnostics Market Forecast
  • 10.4 Europe Blood Cancer Molecular Diagnostics Forecast by Country (2024-2029)
    • 10.4.1 Germany Blood Cancer Molecular Diagnostics Market Forecast
    • 10.4.2 France Blood Cancer Molecular Diagnostics Market Forecast
    • 10.4.3 UK Blood Cancer Molecular Diagnostics Market Forecast
    • 10.4.4 Italy Blood Cancer Molecular Diagnostics Market Forecast
    • 10.4.5 Russia Blood Cancer Molecular Diagnostics Market Forecast
  • 10.5 Middle East & Africa Blood Cancer Molecular Diagnostics Forecast by Region (2024-2029)
    • 10.5.1 Egypt Blood Cancer Molecular Diagnostics Market Forecast
    • 10.5.2 South Africa Blood Cancer Molecular Diagnostics Market Forecast
    • 10.5.3 Israel Blood Cancer Molecular Diagnostics Market Forecast
    • 10.5.4 Turkey Blood Cancer Molecular Diagnostics Market Forecast
    • 10.5.5 GCC Countries Blood Cancer Molecular Diagnostics Market Forecast
  • 10.6 Global Blood Cancer Molecular Diagnostics Forecast by Type (2024-2029)
  • 10.7 Global Blood Cancer Molecular Diagnostics Forecast by Application (2024-2029)

11 Key Players Analysis

  • 11.1 Roche Diagnostics
    • 11.1.1 Roche Diagnostics Company Information
    • 11.1.2 Roche Diagnostics Blood Cancer Molecular Diagnostics Product Offered
    • 11.1.3 Roche Diagnostics Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 11.1.4 Roche Diagnostics Main Business Overview
    • 11.1.5 Roche Diagnostics Latest Developments
  • 11.2 Abbott
    • 11.2.1 Abbott Company Information
    • 11.2.2 Abbott Blood Cancer Molecular Diagnostics Product Offered
    • 11.2.3 Abbott Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 11.2.4 Abbott Main Business Overview
    • 11.2.5 Abbott Latest Developments
  • 11.3 Thermo Fisher
    • 11.3.1 Thermo Fisher Company Information
    • 11.3.2 Thermo Fisher Blood Cancer Molecular Diagnostics Product Offered
    • 11.3.3 Thermo Fisher Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 11.3.4 Thermo Fisher Main Business Overview
    • 11.3.5 Thermo Fisher Latest Developments
  • 11.4 Qiagen
    • 11.4.1 Qiagen Company Information
    • 11.4.2 Qiagen Blood Cancer Molecular Diagnostics Product Offered
    • 11.4.3 Qiagen Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 11.4.4 Qiagen Main Business Overview
    • 11.4.5 Qiagen Latest Developments
  • 11.5 Illumina
    • 11.5.1 Illumina Company Information
    • 11.5.2 Illumina Blood Cancer Molecular Diagnostics Product Offered
    • 11.5.3 Illumina Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 11.5.4 Illumina Main Business Overview
    • 11.5.5 Illumina Latest Developments
  • 11.6 Agilent
    • 11.6.1 Agilent Company Information
    • 11.6.2 Agilent Blood Cancer Molecular Diagnostics Product Offered
    • 11.6.3 Agilent Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 11.6.4 Agilent Main Business Overview
    • 11.6.5 Agilent Latest Developments
  • 11.7 Liferiver
    • 11.7.1 Liferiver Company Information
    • 11.7.2 Liferiver Blood Cancer Molecular Diagnostics Product Offered
    • 11.7.3 Liferiver Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 11.7.4 Liferiver Main Business Overview
    • 11.7.5 Liferiver Latest Developments
  • 11.8 Gpmedical
    • 11.8.1 Gpmedical Company Information
    • 11.8.2 Gpmedical Blood Cancer Molecular Diagnostics Product Offered
    • 11.8.3 Gpmedical Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 11.8.4 Gpmedical Main Business Overview
    • 11.8.5 Gpmedical Latest Developments
  • 11.9 Zeesan
    • 11.9.1 Zeesan Company Information
    • 11.9.2 Zeesan Blood Cancer Molecular Diagnostics Product Offered
    • 11.9.3 Zeesan Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 11.9.4 Zeesan Main Business Overview
    • 11.9.5 Zeesan Latest Developments
  • 11.10 Berry Oncology
    • 11.10.1 Berry Oncology Company Information
    • 11.10.2 Berry Oncology Blood Cancer Molecular Diagnostics Product Offered
    • 11.10.3 Berry Oncology Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 11.10.4 Berry Oncology Main Business Overview
    • 11.10.5 Berry Oncology Latest Developments
  • 11.11 Annoroad
    • 11.11.1 Annoroad Company Information
    • 11.11.2 Annoroad Blood Cancer Molecular Diagnostics Product Offered
    • 11.11.3 Annoroad Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 11.11.4 Annoroad Main Business Overview
    • 11.11.5 Annoroad Latest Developments

12 Research Findings and Conclusion

The global Blood Cancer Molecular Diagnostics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Blood Cancer Molecular Diagnostics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Blood Cancer Molecular Diagnostics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Blood Cancer Molecular Diagnostics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Blood Cancer Molecular Diagnostics players cover Roche Diagnostics, Abbott, Thermo Fisher, Qiagen, Illumina, Agilent, Liferiver, Gpmedical and Zeesan, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

LPI (LP Information)' newest research report, the “Blood Cancer Molecular Diagnostics Industry Forecast” looks at past sales and reviews total world Blood Cancer Molecular Diagnostics sales in 2022, providing a comprehensive analysis by region and market sector of projected Blood Cancer Molecular Diagnostics sales for 2023 through 2029. With Blood Cancer Molecular Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Blood Cancer Molecular Diagnostics industry.

This Insight Report provides a comprehensive analysis of the global Blood Cancer Molecular Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Blood Cancer Molecular Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Blood Cancer Molecular Diagnostics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Blood Cancer Molecular Diagnostics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Blood Cancer Molecular Diagnostics.

This report presents a comprehensive overview, market shares, and growth opportunities of Blood Cancer Molecular Diagnostics market by product type, application, key players and key regions and countries.

Market Segmentation:
Segmentation by type
Polymerase Chain Reaction
Molecular Hybridization
Biochip
Others

Segmentation by application
Hospital
Third-Party Testing Agency
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche Diagnostics
Abbott
Thermo Fisher
Qiagen
Illumina
Agilent
Liferiver
Gpmedical
Zeesan
Berry Oncology
Annoroad

Buy now